In the fight against cancer, immunotherapy—which aims to boost the body's natural defenses against cancer—is experiencing remarkable growth. Most of these treatments are based on CD8 T lymphocytes, ...

Peripheral blood CD4+/CD8+ t cell ratio predicts HBsAg clearance in inactive HBsAg carriers treated with peginterferon alpha Peer-Reviewed Publication ...

Zhuo, C., et al. (2025). Single-cell sequencing reveals the expansion and diversity of T cell subsets in the bone marrow ...

CD4/CD8 T-cell selection of the apheresis product improved CAR T-cell manufacturing feasibility as well as heightened inflammatory toxicities, leading to dose de-escalation. The complete remission ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions ...

The molecular markers CD4 and CD8—defining helper T cells and killer T cells, respectively—were once considered mutually exclusive. But "double positive" CD4+-CD8+ T cells have lately been ...

The body's first line of defense against tuberculosis (TB) involves immune cells that suppress lung inflammation instead of ...

The presence of CD107a, an activated CD8 T-cell degranulation marker, and granulysin, which is cytolytic, pro-inflammatory, and expressed at baseline by NK cells, as well as by activated CD4 and ...

Expanded CAR T cells were predominantly CD4–CD8 double-negative and EBER negative. Replication-competent lentivirus was undetectable in the blood at 6 and 12 months after cilta-cel therapy.